09/06/21 -"With COVID-19 vaccine programmes fast gaining pace, a gradual recovery is expected in the Anti-Histamine markets heading into H2 21, indicating increasing demand for the high-margin drug, Bilastine. ..."
Pages
46
Language
English
Published on
09/06/21
You may also be interested by these reports :
20/07/26
Samsung Biologics announced a tender offer to acquire PolyPeptide Group for CHF 44.31/share, or CHF 1.46bn in market capitalisation, a premium of 6% ...
14/07/26
Pharmas’ AI investments pour broadly into two areas: Compute infrastructure, and AI models and platforms. Neither provides a long-term competitive ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...
06/07/26
Our target price has been adjusted downward as we have removed the 20% premium associated with peer-based valuation metrics. This adjustment is due ...